KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to -$71.0 million.

  • Takeda Pharmaceutical's Change in Receivables fell 18522.5% to -$71.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $104.0 million, marking a year-over-year decrease of 5002.79%. This contributed to the annual value of -$387.1 million for FY2025, which is 46956.55% down from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Change in Receivables stood at -$71.0 million, which was down 18522.5% from -$66.5 million recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Change in Receivables high stood at $1.2 billion for Q4 2021, and its period low was -$659.4 million during Q2 2023.
  • For the 5-year period, Takeda Pharmaceutical's Change in Receivables averaged around $95.0 million, with its median value being $85.3 million (2024).
  • In the last 5 years, Takeda Pharmaceutical's Change in Receivables skyrocketed by 36120.62% in 2021 and then crashed by 37458.81% in 2023.
  • Takeda Pharmaceutical's Change in Receivables (Quarter) stood at $1.2 billion in 2021, then tumbled by 92.52% to $90.4 million in 2022, then grew by 6.93% to $96.7 million in 2023, then dropped by 13.75% to $83.4 million in 2024, then crashed by 185.23% to -$71.0 million in 2025.
  • Its Change in Receivables was -$71.0 million in Q4 2025, compared to -$66.5 million in Q3 2025 and $332.3 million in Q2 2025.